Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan · Delayed Price · Currency is TWD 29.70
-0.15 (-0.50%)
Nov 13, 2026, 1:24 PM CST
Senhwa Biosciences Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,378 | 771.78 | 1,026 | 1,319 | 1,619 | 2,033 |
Cash & Short-Term Investments | 1,378 | 771.78 | 1,026 | 1,319 | 1,619 | 2,033 |
Cash Growth | 66.91% | -24.77% | -22.20% | -18.55% | -20.34% | -14.19% |
Accounts Receivable | 0.02 | - | - | - | - | 0.19 |
Other Receivables | 0.45 | 0.14 | 0.18 | 10.59 | 8.64 | 7 |
Receivables | 0.47 | 0.14 | 0.18 | 10.59 | 8.64 | 7.18 |
Prepaid Expenses | 39.66 | 8.49 | 8.69 | 6.74 | 5.51 | 1.62 |
Other Current Assets | - | - | - | - | 4.18 | 3.35 |
Total Current Assets | 1,418 | 780.41 | 1,035 | 1,336 | 1,637 | 2,045 |
Property, Plant & Equipment | 15.72 | 22.83 | 17.2 | 14.37 | 15.75 | 15.42 |
Long-Term Investments | 0 | 0 | 0 | 0.13 | 0.13 | 0.13 |
Other Intangible Assets | 0.14 | 0.05 | 0.14 | 0.23 | - | 0.07 |
Other Long-Term Assets | 17.42 | 15.98 | 13.78 | 12.46 | 1.54 | 1.32 |
Total Assets | 1,452 | 819.26 | 1,066 | 1,363 | 1,655 | 2,062 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | - | 33.4 | 21.58 | 32.37 | 22.04 | 75.63 |
Current Portion of Leases | 9.65 | 9.16 | 7.16 | 6.31 | 8.18 | 5.17 |
Current Income Taxes Payable | - | 0.08 | 0.14 | - | - | - |
Other Current Liabilities | 53.59 | 2.7 | 2.21 | 4.2 | 2.73 | 1.43 |
Total Current Liabilities | 63.24 | 45.35 | 31.09 | 42.89 | 32.95 | 82.23 |
Long-Term Leases | 5.84 | 12.96 | 7.84 | 3.29 | 7.98 | 10.21 |
Total Liabilities | 69.08 | 58.3 | 38.93 | 46.18 | 40.93 | 92.44 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1,149 | 899.04 | 897.44 | 897.44 | 897.44 | 897.44 |
Additional Paid-In Capital | 606.44 | 181.92 | 469.58 | 765.88 | 1,116 | 1,444 |
Retained Earnings | -326.23 | -266.15 | -293.87 | -296.31 | -349.63 | -329.26 |
Treasury Stock | -49.36 | -49.36 | -51.35 | -51.35 | -51.35 | -38.11 |
Comprehensive Income & Other | 2.64 | -4.48 | 5.24 | 1.49 | 1.35 | -5.24 |
Shareholders' Equity | 1,383 | 760.96 | 1,027 | 1,317 | 1,614 | 1,969 |
Total Liabilities & Equity | 1,452 | 819.26 | 1,066 | 1,363 | 1,655 | 2,062 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 15.49 | 22.12 | 15 | 9.6 | 16.16 | 15.38 |
Net Cash (Debt) | 1,363 | 749.67 | 1,011 | 1,309 | 1,603 | 2,017 |
Net Cash Growth | 70.02% | -25.85% | -22.78% | -18.33% | -20.54% | -14.14% |
Net Cash Per Share | 14.80 | 8.40 | 11.34 | 14.68 | 17.97 | 22.50 |
Filing Date Shares Outstanding | 101.36 | 89.39 | 89.19 | 89.19 | 88.63 | 89.31 |
Total Common Shares Outstanding | 101.36 | 89.39 | 89.19 | 89.19 | 88.63 | 89.31 |
Working Capital | 1,355 | 735.06 | 1,004 | 1,293 | 1,605 | 1,963 |
Book Value Per Share | 13.64 | 8.51 | 11.52 | 14.77 | 18.21 | 22.05 |
Tangible Book Value | 1,382 | 760.92 | 1,027 | 1,317 | 1,614 | 1,969 |
Tangible Book Value Per Share | 13.64 | 8.51 | 11.51 | 14.77 | 18.21 | 22.05 |